Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
CA 2277473 C · Owner: Pfizer Limited · Inventors: Fox, David Nathan Abraham
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula (I), wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents H or C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 represents a 5- or 6membered heterocyclic ring, the ring being optionally substituted; R4 represents a 4-, 5-, 6- or 7-membered heterocyclic ring the ring being , optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring the ring system as a whole being optionally substituted; X represents CH or N; and L is absent, or represents a cyclic group of formula (Ia) or represents a , chain of formula (Ib) and pharmaceutically acceptable salts thereof; are useful in therapy, in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 6, 1998 and granted August 12, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 6, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 6, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.